Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$1.75
+4.2%
$2.05
$1.55
$8.60
$42.96M0.62358,307 shs147,550 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$6.42
+1.7%
$7.90
$3.16
$10.13
$1.49B0.856.06 million shs5.48 million shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.45
-3.9%
$2.75
$0.50
$3.22
$368.31M1.682.78 million shs2.31 million shs
Organigram Holdings Inc. stock logo
OGI
Organigram
$1.86
$2.09
$0.97
$2.91
$191.95M1.091.35 million shs751,385 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-5.62%-6.67%-23.64%+0.60%-79.03%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-1.87%-2.02%-14.96%-30.35%+35.41%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-3.77%-5.90%-6.93%+2.41%+1.19%
Organigram Holdings Inc. stock logo
OGI
Organigram
-3.63%-0.53%-30.60%+13.41%-7.68%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
1.8725 of 5 stars
3.32.00.00.01.03.30.6
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.8909 of 5 stars
3.62.00.04.41.71.70.6
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.9855 of 5 stars
3.52.00.04.22.61.70.6
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.50
Moderate Buy$24.671,309.52% Upside
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.11
Buy$12.6997.62% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.50124.49% Upside
Organigram Holdings Inc. stock logo
OGI
Organigram
3.00
BuyN/AN/A

Current Analyst Ratings

Latest OGI, ARDX, HRTX, and AADI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
4/17/2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$13.00 ➝ $14.00
4/15/2024
Organigram Holdings Inc. stock logo
OGI
Organigram
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
4/11/2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/5/2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/5/2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
3/13/2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$4.00 ➝ $5.00
2/23/2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$12.00 ➝ $15.00
2/23/2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$24.35M1.76N/AN/A$4.29 per share0.41
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$124.46M12.00N/AN/A$0.72 per share8.92
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$127.04M2.90N/AN/A($0.23) per share-10.65
Organigram Holdings Inc. stock logo
OGI
Organigram
$120.01M1.60N/AN/A$2.48 per share0.75

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.44N/AN/AN/A-270.04%-52.53%-44.29%5/8/2024 (Estimated)
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$66.07M-$0.30N/A64.20N/A-53.08%-43.57%-26.03%5/2/2024 (Confirmed)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$110.56M-$0.86N/AN/AN/A-87.02%N/A-50.61%5/7/2024 (Confirmed)
Organigram Holdings Inc. stock logo
OGI
Organigram
-$184.34M-$0.80N/AN/AN/A-173.48%-30.94%-27.70%4/30/2024 (Estimated)

Latest OGI, ARDX, HRTX, and AADI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.08N/A+$0.08N/AN/AN/A  
5/2/2024N/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.13N/A+$0.13N/AN/AN/A  
3/13/2024Q4 2023
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$0.67-$0.60+$0.07-$0.60$6.46 million$6.33 million
3/12/2024Q4 2023
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.15-$0.07+$0.08-$0.07$30.98 million$34.23 million
2/22/202412/31/2023
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.09-$0.12-$0.03-$0.12$34.26 million$34.36 million    
2/13/2024Q1 2024
Organigram Holdings Inc. stock logo
OGI
Organigram
-$0.10-$0.14-$0.04-$0.14$28.61 million$26.78 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.72
4.48
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.30
4.88
4.64
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.37
1.84
Organigram Holdings Inc. stock logo
OGI
Organigram
N/A
4.28
2.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Organigram Holdings Inc. stock logo
OGI
Organigram
34.63%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
35.80%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
5.50%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
6.40%
Organigram Holdings Inc. stock logo
OGI
Organigram
0.09%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
8924.55 million15.76 millionOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
267232.69 million219.89 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
126150.33 million140.71 millionOptionable
Organigram Holdings Inc. stock logo
OGI
Organigram
984103.20 million103.11 millionOptionable

OGI, ARDX, HRTX, and AADI Headlines

SourceHeadline
Are Medical Stocks Lagging  OrganiGram (OGI) This Year?Are Medical Stocks Lagging OrganiGram (OGI) This Year?
finance.yahoo.com - April 26 at 11:11 AM
Are Medical Stocks Lagging OrganiGram (OGI) This Year?Are Medical Stocks Lagging OrganiGram (OGI) This Year?
zacks.com - April 26 at 10:46 AM
Canadian Cannabis Sales Drop AgainCanadian Cannabis Sales Drop Again
newcannabisventures.com - April 26 at 1:08 AM
Organigram (NASDAQ:OGI) Upgraded by Alliance Global Partners to "Buy"Organigram (NASDAQ:OGI) Upgraded by Alliance Global Partners to "Buy"
americanbankingnews.com - April 16 at 4:50 AM
Organigram (NASDAQ:OGI) Lifted to Buy at Alliance Global PartnersOrganigram (NASDAQ:OGI) Lifted to Buy at Alliance Global Partners
marketbeat.com - April 15 at 9:11 AM
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
markets.businessinsider.com - April 11 at 1:36 PM
Organigram Recognized for Executive Gender Diversity by the Globe & Mails Women Lead Here Report for the Fourth Consecutive YearOrganigram Recognized for Executive Gender Diversity by the Globe & Mail's Women Lead Here Report for the Fourth Consecutive Year
stockhouse.com - April 10 at 5:10 PM
Q2 2024 EPS Estimates for Organigram Holdings Inc. Increased by Atb Cap Markets (NASDAQ:OGI)Q2 2024 EPS Estimates for Organigram Holdings Inc. Increased by Atb Cap Markets (NASDAQ:OGI)
marketbeat.com - April 5 at 8:21 AM
Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail SalesOrganigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales
finance.yahoo.com - April 3 at 8:37 AM
Organigrams Popular SHRED Brand Surpasses $200 Million in Yearly Retail SalesOrganigram's Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales
businesswire.com - April 3 at 8:06 AM
Organigram Successfully Closes Previously Announced Underwritten Public OfferingOrganigram Successfully Closes Previously Announced Underwritten Public Offering
businesswire.com - April 2 at 8:51 AM
Organigram (NASDAQ:OGI) Stock Price Down 6.3%Organigram (NASDAQ:OGI) Stock Price Down 6.3%
marketbeat.com - March 30 at 12:43 AM
Why OrganiGram (OGI) Might Surprise This Earnings SeasonWhy OrganiGram (OGI) Might Surprise This Earnings Season
zacks.com - March 28 at 9:56 AM
Why OrganiGram (OGI) Stock Is DivingWhy OrganiGram (OGI) Stock Is Diving
msn.com - March 27 at 3:18 PM
Organigram Sells Units to Raise C$25 MIllionOrganigram Sells Units to Raise C$25 MIllion
newcannabisventures.com - March 27 at 10:18 AM
Organigram Announces Pricing of Overnight Marketed Public OfferingOrganigram Announces Pricing of Overnight Marketed Public Offering
businesswire.com - March 27 at 8:56 AM
Organigram Announces Launch of Overnight Marketed Public OfferingOrganigram Announces Launch of Overnight Marketed Public Offering
businesswire.com - March 26 at 7:06 PM
Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter InvestmentOrganigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment
businesswire.com - March 26 at 1:36 PM
OGI Sep 2024 6.000 callOGI Sep 2024 6.000 call
finance.yahoo.com - March 26 at 12:10 AM
OGI Jun 2024 4.000 putOGI Jun 2024 4.000 put
finance.yahoo.com - March 26 at 12:10 AM
Organigram ‘assessing options’ after unfavorable ruling on cannabis ediblesOrganigram ‘assessing options’ after unfavorable ruling on cannabis edibles
mjbizdaily.com - March 26 at 12:10 AM
The Marijuana Stocks Could See A Rise This WeekThe Marijuana Stocks Could See A Rise This Week
marijuanastocks.com - March 24 at 9:40 AM
Organigram Receives Health Canadas Final Redetermination on JoltsOrganigram Receives Health Canada's Final Redetermination on Jolts
businesswire.com - March 22 at 7:00 PM
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
investorplace.com - March 21 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Aadi Bioscience logo

Aadi Bioscience

NASDAQ:AADI
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Ardelyx logo

Ardelyx

NASDAQ:ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Heron Therapeutics logo

Heron Therapeutics

NASDAQ:HRTX
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Organigram logo

Organigram

NASDAQ:OGI
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.